111 related articles for article (PubMed ID: 6148118)
1. Zetidoline, a new antipsychotic. First controlled trial in acute schizophrenia.
Silverstone T; Levine S; Freeman HL; Dubini A
Br J Psychiatry; 1984 Sep; 145():294-9. PubMed ID: 6148118
[TBL] [Abstract][Full Text] [Related]
2. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
[TBL] [Abstract][Full Text] [Related]
3. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.
Wright P; Lindborg SR; Birkett M; Meehan K; Jones B; Alaka K; Ferchland-Howe I; Pickard A; Taylor CC; Roth J; Battaglia J; Bitter I; Chouinard G; Morris PL; Breier A
Can J Psychiatry; 2003 Dec; 48(11):716-21. PubMed ID: 14733451
[TBL] [Abstract][Full Text] [Related]
4. Dose-response relationship of sertindole and haloperidol using the pharmacopsychometric triangle.
Bech P; Tanghøj P; Andreasson K; Overø KF
Acta Psychiatr Scand; 2011 Feb; 123(2):154-61. PubMed ID: 20560900
[TBL] [Abstract][Full Text] [Related]
5. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks.
Kane JM; Crandall DT; Marcus RN; Eudicone J; Pikalov A; Carson WH; Swyzen W
Schizophr Res; 2007 Sep; 95(1-3):143-50. PubMed ID: 17644313
[TBL] [Abstract][Full Text] [Related]
6. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.
Kapur S; Zipursky R; Jones C; Remington G; Houle S
Am J Psychiatry; 2000 Apr; 157(4):514-20. PubMed ID: 10739409
[TBL] [Abstract][Full Text] [Related]
7. Short-term double-blind trial of pipothiazine palmitate and haloperidol in the acute phase of schizophrenia.
Bechelli LP; Navas-Filho F
Encephale; 1986; 12(3):121-5. PubMed ID: 2876879
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group.
Daniel DG; Wozniak P; Mack RJ; McCarthy BG
Psychopharmacol Bull; 1998; 34(1):61-9. PubMed ID: 9564200
[TBL] [Abstract][Full Text] [Related]
9. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.
Allan ER; Sison CE; Alpert M; Connolly B; Crichton J
Psychopharmacol Bull; 1998; 34(1):71-4. PubMed ID: 9564201
[TBL] [Abstract][Full Text] [Related]
10. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
Keefe RS; Seidman LJ; Christensen BK; Hamer RM; Sharma T; Sitskoorn MM; Lewine RR; Yurgelun-Todd DA; Gur RC; Tohen M; Tollefson GD; Sanger TM; Lieberman JA
Am J Psychiatry; 2004 Jun; 161(6):985-95. PubMed ID: 15169686
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Tada M; Shirakawa K; Matsuoka N; Mutoh S
Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
[TBL] [Abstract][Full Text] [Related]
12. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
Andrezina R; Josiassen RC; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; Iwamoto T
Psychopharmacology (Berl); 2006 Oct; 188(3):281-92. PubMed ID: 16953381
[TBL] [Abstract][Full Text] [Related]
13. A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database.
Fleischhacker WW; Lemmens P; van Baelen B
Pharmacopsychiatry; 2001 May; 34(3):104-10. PubMed ID: 11434401
[TBL] [Abstract][Full Text] [Related]
14. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
Timdahl K; Carlsson A; Stening G
Hum Psychopharmacol; 2007 Jul; 22(5):315-25. PubMed ID: 17542047
[TBL] [Abstract][Full Text] [Related]
15. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
[TBL] [Abstract][Full Text] [Related]
17. Atypical neuroleptics in acute schizophrenia: a double-blind comparative study of remoxipride and haloperidol.
den Boer JA; Westenberg HG
Psychopharmacol Bull; 1990; 26(1):99-107. PubMed ID: 1973547
[TBL] [Abstract][Full Text] [Related]
18. Aripiprazole: new drug. Just another neuroleptic.
Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
[TBL] [Abstract][Full Text] [Related]
19. A review of the safety and tolerability of sertindole.
Hale AS
Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S65-70. PubMed ID: 9690973
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia.
Kane JM; Potkin SG; Daniel DG; Buckley PF
J Clin Psychiatry; 2011 Feb; 72(2):194-204. PubMed ID: 20673553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
